Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets

Cancer Letters

Volumn 317, Issue 2, 2012, Pages 207-217

  Gest, Caroline ^a   Mirshahi, Pezhman ^a,b   Li, Hong ^a   Pritchard, Linda Louise ^e   Joimel, Ulrich ^a   Blot, Emmanuel ^a,c   Chidiac, Jean ^d   Poletto, Bernard ^d   Vannier, Jean Pierre ^a   Varin, Remi ^a   Mirshahi, Massoud ^b   Cazin, Lionel ^a   Pujade Lauraine, Eric ^d   Soria, Jeannette ^b,d   Soria, Claudine ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c Centre anti cancéreux Henri Becquerel   (France)

^d HÔTEL DIEU   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Cancer cell invasion; IGF; IGF IR; Ovarian cancer; Rho; Stat3; Vasculogenic mimicry

Indexed keywords

DASATINIB; HYDROLASE INHIBITOR; PROTEIN INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SOMATOMEDIN C RECEPTOR; STAT3 PROTEIN; TUMOR MARKER;

ARTICLE; ASCITES FLUID; CANCER CELL CULTURE; CANCER INVASION; CANCER RESEARCH; CANCER STAGING; CELL INVASION; CELL ISOLATION; CELL POPULATION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR MIMICRY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MODELS, BIOLOGICAL; OVARIAN NEOPLASMS; RECEPTOR, IGF TYPE 1; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84856608439     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.026     Document Type: Article

References (51)

1. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med. 2004, 351:2519-2529.
2. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., Bauknecht T., Richter B., Warm M., Schroder W., Olbricht S., Nitz U., Jackisch C., Emons G., Wagner U., Kuhn W., Pfisterer J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003, 95:1320-1329.
3. Li H.Z., Wang Y., Gao Y., Shao J., Zhao X.L., Deng W.M., Liu Y.X., Yang J., Yao Z. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer. Mol. Cancer Res. 2008, 6:917-928.
4. Song Y., Wilkins P., Hu W., Murthy K.S., Chen J., Lee Z., Oyesanya R., Wu J., Barbour S.E., Fang X. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells. Biochem. J. 2007, 406:427-436.
5. Obermair A., Wasicky R., Kaider A., Preyer O., Losch A., Leodolter S., Kolbl H. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 1999, 138:175-182.
6. Labiche A., Elie N., Herlin P., Denoux Y., Crouet H., Heutte N., Joly F., Heron J.F., Gauduchon P., Henry-Amar M. Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histol. Histopathol. 2009, 24:425-435.
7. Duncan T.J., Al-Attar A., Rolland P., Scott I.V., Deen S., Liu D.T., Spendlove I., Durrant L.G. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?. Clin. Cancer Res. 2008, 14:3030-3035.
8. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
9. Dejana E., Spagnuolo R., Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost. 2001, 86:308-315.
10. Kobold S., Hegewisch-Becker S., Oechsle K., Jordan K., Bokemeyer C., Atanackovic D. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?. Oncologist 2009, 14:1242-1251.
11. Sood A.K., Fletcher M.S., Zahn C.M., Gruman L.M., Coffin J.E., Seftor E.A., Hendrix M.J. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol. Ther. 2002, 1:661-664.
12. Zhu P., Ning Y., Yao L., Chen M., Xu C. The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia. J. Exp. Clin. Cancer Res. 2010, 29:124.
13. Shaw L.M. Tumor cell invasion assays. Methods Mol. Biol. 2005, 294:97-105.
14. Mills G.B., Eder A., Fang X., Hasegawa Y., Mao M., Lu Y., Tanyi J., Tabassam F.H., Wiener J., Lapushin R., Yu S., Parrott J.A., Compton T., Tribley W., Fishman D., Stack M.S., Gaudette D., Jaffe R., Furui T., Aoki J., Erickson J.R. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res. 2002, 107:259-283.
15. Zebrowski B.K., Liu W., Ramirez K., Akagi Y., Mills G.B., Ellis L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 1999, 6:373-378.
16. Ayhan A., Gultekin M., Taskiran C., Dursun P., Firat P., Bozdag G., Celik N.Y., Yuce K. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int. J. Gynecol. Cancer 2007, 17:68-75.
17. Miyamoto S., Hirata M., Yamazaki A., Kageyama T., Hasuwa H., Mizushima H., Tanaka Y., Yagi H., Sonoda K., Kai M., Kanoh H., Nakano H., Mekada E. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res. 2004, 64:5720-5727.
18. Saltzman A.K., Hartenbach E.M., Carter J.R., Contreras D.N., Twiggs L.B., Carson L.F., Ramakrishnan S. Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer. Gynecol. Obstet. Invest. 1999, 47:200-204.
19. Ades E.W., Candal F.J., Swerlick R.A., George V.G., Summers S., Bosse D.C., Lawley T.J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Invest. Dermatol. 1992, 99:683-690.
20. Mirshahi P., Rafii A., Vincent L., Berthaut A., Varin R., Kalantar G., Marzac C., Calandini O.A., Marie J.P., Soria C., Soria J., Mirshahi M. Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 2009, 23:1039-1048.
21. Gao X., Xu Z. Mechanisms of action of angiogenin. Acta Biochim. Biophys. Sin. (Shanghai) 2008, 40:619-624.
22. Vasse M., Pourtau J., Trochon V., Muraine M., Vannier J.P., Lu H., Soria J., Soria C. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 1999, 19:1835-1842.
23. van Cruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int. J. Cancer 2005, 117:883-888.
24. Maniotis A.J., Chen X., Garcia C., DeChristopher P.J., Wu D., Pe'er J., Folberg R. Control of melanoma morphogenesis, endothelial survival, and perfusion by extracellular matrix. Lab. Invest. 2002, 82:1031-1043.
25. Neeman M., Abramovitch R., Schiffenbauer Y.S., Tempel C. Regulation of angiogenesis by hypoxic stress: from solid tumours to the ovarian follicle. Int. J. Exp. Pathol. 1997, 78:57-70.
26. Burger R.A., Brady M.F., Bookman M.A., Walker J.L., Homesley H.D., Fowler J., Monk B.J., Greer B.E., Boente M., Liang S.X. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J. Clin. Oncol. (Meet. Abstr.) 2010, 28:LBA1.
27. Zhang S., Zhang D., Sun B. Vasculogenic mimicry: current status and future prospects. Cancer Lett. 2007, 254:157-164.
28. Kohn E.C., Travers L.A., Kassis J., Broome U., Klominek J. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn. Cytopathol. 2005, 33:300-308.
29. Ren J., Xiao Y.J., Singh L.S., Zhao X., Zhao Z., Feng L., Rose T.M., Prestwich G.D., Xu Y. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 2006, 66:3006-3014.
30. Silver D.L., Naora H., Liu J., Cheng W., Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004, 64:3550-3558.
31. Burke W.M., Jin X., Lin H.J., Huang M., Liu R., Reynolds R.K., Lin J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20:7925-7934.
32. Cheng J.Q., Lindsley C.W., Cheng G.Z., Yang H., Nicosia S.V. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005, 24:7482-7492.
33. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997, 17:337-342.
34. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., Bornmann W., Bromberg J.F. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007, 9:R32.
35. Noskova V., Ahmadi S., Asander E., Casslen B. Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol. Oncol. 2009, 115:121-126.
36. Zha J., Lackner M.R. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin. Cancer Res. 2010, 16:2512-2517.
37. Zhang H., Fagan D.H., Zeng X., Freeman K.T., Sachdev D., Yee D. Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation. Oncogene 2010, 29:2517-2527.
38. Brokaw J., Katsaros D., Wiley A., Lu L., Su D., Sochirca O., de la Longrais I.A., Mayne S., Risch H., Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25:346-354.
39. Attias-Geva Z., Bentov I., Fishman A., Werner H., Bruchim I. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol. Oncol. 2011, 121:383-389.
40. Bessard A., Fremin C., Ezan F., Fautrel A., Gailhouste L., Baffet G. RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene 2008, 27:5315-5325.
41. Horiuchi A., Kikuchi N., Osada R., Wang C., Hayashi A., Nikaido T., Konishi I. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer. Cancer Sci. 2008, 99:2532-2539.
42. Pille J.Y., Li H., Blot E., Bertrand J.R., Pritchard L.L., Opolon P., Maksimenko A., Lu H., Vannier J.P., Soria J., Malvy C., Soria C. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 2006, 17:1019-1026.
43. Denoyelle C., Vasse M., Korner M., Mishal Z., Ganne F., Vannier J.P., Soria J., Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001, 22:1139-1148.
44. Sood A.K., Fletcher M.S., Coffin J.E., Yang M., Seftor E.A., Gruman L.M., Gershenson D.M., Hendrix M.J. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am. J. Obstet. Gynecol. 2004, 190:899-909.
45. Bond M., Chase A.J., Baker A.H., Newby A.C. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. 2001, 50:556-565.
46. Konecny G.E., Glas R., Dering J., Manivong K., Qi J., Finn R.S., Yang G.R., Hong K.L., Ginther C., Winterhoff B., Gao G., Brugge J., Slamon D.J. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br. J. Cancer 2009, 101:1699-1708.
47. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., Mathieson T., Perrin J., Raida M., Rau C., Reader V., Sweetman G., Bauer A., Bouwmeester T., Hopf C., Kruse U., Neubauer G., Ramsden N., Rick J., Kuster B., Drewes G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25:1035-1044.
48. Sood A.K., Coffin J.E., Schneider G.B., Fletcher M.S., DeYoung B.R., Gruman L.M., Gershenson D.M., Schaller M.D., Hendrix M.J. Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am. J. Pathol. 2004, 165:1087-1095.
49. Debidda M., Wang L., Zang H., Poli V., Zheng Y. A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J. Biol. Chem. 2005, 280:17275-17285.
50. Rojas A., Liu G., Coleman I., Nelson P.S., Zhang M., Dash R., Fisher P.B., Plymate S.R., Wu J.D. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. Oncogene 2011, 30:2345-2355.
51. Sachdev P., Jiang Y.X., Li W., Miki T., Maruta H., Nur E.K.M.S., Wang L.H. Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J. Biol. Chem. 2001, 276:26461-26471.